Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Key EU Panel Backs Padcev Again for Bladder Cancer
Astellas Pharma/Seagen’s Padcev (enfortumab vedotin) has inched closer to approval in Europe as the first antibody-drug conjugate (ADC) to treat advanced urothelial cancer in the region, with a key EU panel re-adopting its recommendation after a review of new safety…
To read the full story
Related Article
- Astellas’ Padcev Receives Bladder Cancer Nod in Europe
April 15, 2022
- Astellas’ Padcev Gets Key European Backing for Bladder Cancer
December 21, 2021
- EMA Accepts Regulatory Filing of Enfortumab Vedotin: Astellas/Seagen
March 29, 2021
- Astellas Seeks Japan Nod for Padcev
March 12, 2021
- Astellas/Seattle Genetics Nabs FDA OK for 1st-in-Class ADC
December 20, 2019
BUSINESS
- Toho Subsidiary Suffers Data Breach, HCP Info Exposed
October 20, 2026
- Veritas, Toray Pin Down Hit Compounds for PCSK9 mRNA Drugs
October 20, 2026
- Insmed’s Brinsupri Hits Japan Market for NCFB
October 20, 2026
- Ex-Alfresa Chairman Arata Watanabe Dies at 85
October 20, 2026
- TS Alfresa-Backed Drone Council Inks Pact with Hiroshima
October 19, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…